Author: admin123TerRe

ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava.The company helps its corporate clients with their product strategy, in- and out-licensing efforts, including asset valuation (NPV, rNPV), M&A scouting, complex due diligence and dealmaking.ambiom also provides input on regulatory matters, support in pricing and reimbursement decisions and communication with decision-making authorities. The company guides products from the beginning – the basic science – all the way to commercialization or spin-offs.Our guest on the podcast this week is the founder and CEO of ambiom, Adam Marťák. We discuss the biotech scene in eastern Europe,…

Citation: Kinsler G, Li Y, Sherlock G, Petrov DA (2024) A high-resolution two-step evolution experiment in yeast reveals a shift from pleiotropic to modular adaptation. PLoS Biol 22(12): e3002848. https://doi.org/10.1371/journal.pbio.3002848Academic Editor: J. Arjan G. M. de Visser, Wageningen University, NETHERLANDS, KINGDOM OF THEReceived: April 19, 2024; Accepted: September 17, 2024; Published: December 5, 2024Copyright: © 2024 Kinsler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Data Availability: All relevant data are within the…

This is just a quick note to say that I will be on a panel at San Diego Comic Con again this year and would like to invite you all to come say hi! Once again, the panel is organized by the visionary Steve Broback, head of Dent the Future, an organization committed to advancing new and creative ideas throughout society, especially in technology. Given my frequent participation in Dent events, they also seem to be keenly interested in genetics and its future. Our panel is about the science of Avatar: The Way of Water. Joining me will be Michelle…

Newsletter Signup – Under Article / In Page”*” indicates required fields When German scientists posted data in 2022 showing that CAR-T cell therapy could be effective in treating systemic lupus erythematosus, interest in the field quickly took off. More recently, spurring interest even further, the researchers posted an update in February 2024, showing results from a case series in which 15 autoimmune disease patients, eight of which had systemic lupus erythematosus, all achieved complete remission after receiving a single infusion of CAR-T therapy.Lupus, which affects around five million people worldwide, occurs when the immune system attacks its own tissues. The…

AbstractOutbreaks of fungal diseases have devastated plants and animals throughout history. Over the past century, the repeated emergence of coffee wilt disease caused by the fungal pathogen Fusarium xylarioides severely impacted coffee production across sub-Saharan Africa. To improve the disease management of such pathogens, it is crucial to understand their genetic structure and evolutionary potential. We compared the genomes of 13 historic strains spanning 6 decades and multiple disease outbreaks to investigate population structure and host specialisation. We found that F. xylarioides comprised at least 4 distinct lineages: 1 host-specific to Coffea arabica, 1 to C. canephora var. robusta, and…

Post provided by Coralie Williams Have you ever wondered if your simulation study could be replicated? The replication crisis has been a hot topic in empirical research for years, but it’s only recently that we’ve started discussing it in statistical method research (Boulesteix et al., 2020; Luijken et al., 2024). Methodological research often relies on simulations – computer experiments that assess how well statistical methods perform under predefined conditions. Simulations are a valuable tool for evaluation and comparison, but just like any scientific experiment, they face challenges with reproducibility. These challenges could be due to two key issues: (1) selective…

Newsletter Signup – Under Article / In Page”*” indicates required fields The clinical development process is long, often exceeding 10 years from discovery through regulatory approval for a drug candidate. Whereas established companies have experience in all clinical trial phases, in-house regulatory expertise, and are equipped to run large, standardized trials, smaller biotechs have limited financing, fewer established processes, and may outsource parts of their drug development process to specialized vendors. In this article, we’ll explore challenges in clinical trial design and show how choosing the right software solution can drastically improve the probability of clinical trial success.Challenges in clinical trial…

Citation: Plastrik AR, Zaher HS (2024) Not just a garbage truck: No-go decay plays a role during embryo development in zebrafish. PLoS Biol 22(12): e3002925. https://doi.org/10.1371/journal.pbio.3002925Published: December 6, 2024Copyright: © 2024 Plastrik, Zaher. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Funding: Work in the Zaher Lab is supported by the NIH grants R01GM112641 to HSZ and R01GM141474 to HSZ. The funders had no role in study design, data collection and analysis, decision to publish,…

Photo credit: Butterfly mimicry, by Antony Trivet, CC BY-SA 4.0 , via Wikimedia Commons. I have been reviewing a new collection from Cambridge University Press, Darwin Mythology: Debunking Myths, Correcting Falsehoods. (See my earlier posts here and here.) James G. Lennox opens his essay about Darwin’s views on teleology with Friedrich Engels’s statement in a letter to Karl Marx. Engels exulted that Darwin had demolished teleology. This is a view that is commonplace among many Darwinian biologists, as well as historians. Lennox, however, calls it a myth that Darwin banished teleology from nature. Lennox defines teleology thus: “A teleological explanation is…

Newsletter Signup – Under Article / In Page”*” indicates required fields As 2024 comes to a close, and while we will soon be thinking about 2025 and the trends that will shape the biotech industry, now is a good time to look back at what happened this year. Earlier this year, we collected expert insight into what the year 2024 would look like for biotech – from AI reshaping the industry, and CRISPR’s growth potential to strong merger and acquisition (M&A) activity – which of those predicted trends became a reality in 2024?According to Artem Trotsyuk, operating partner at LongeVC, “the…